Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Grail Inc

GRAL ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$79.59

▼ -3.57%

Market Cap $3.55B · Vol 140.78K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.55B

Mid Cap

Div Yield

N/A

EPS Growth

+8.02%

YoY

RSI (14)

68.73

Momentum

Beta

N/A

vs Market

52W High

$118.53

32.85% below

52W Low

$30.85

157.99% above

Volume

140.78K

Avg 239.76K

P/B

1.34

Price-to-book

ROE

-16.07%

Return on equity

Free Float

94.98%

Public shares

Shariah Compliance8 STANDARDS

✗ Grail Inc (GRAL) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GRAL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.61%

+17.32%

+15.41%

+36.99%

YTD

-7.01%

+133.61%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$147.17M
Net Income	$-408,351,000.00
Revenue Growth (YoY)	+25.72%
Gross Margin	-42.52%
Operating Margin	-362.97%
Net Profit Margin	-277.47%
ROE	-16.07%
ROA · ROIC	-18.10% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	21.37
P/B	1.34
P/FCF	N/A
EPS Growth	+8.02%
Outstanding Shares	44.67M

Technical Indicators

50-Day SMA	$69.93
200-Day SMA	$73.27
RSI (14)	68.73
Beta	N/A
52-Week High	$118.53
52-Week Low	$30.85

Volume Today	140.78K
Avg Daily Volume (30D)	239.76K
Relative Volume	0.59x
Volatility (10D)	55.95
Volatility (30D)	85.96
Free Float	94.98%

Analyst Consensus

BUY

Current Price $79.59

Mean Target $72.38

52W Low$30.85 52W High$118.53

Current

Target

$30.85 $118.53

Current Analyst target

-9.07% downside risk · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01N6CGX05

ISINUS3847471014

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.01% ONC BeOne Medicines AG -0.15% RVMD Revolution Medicines Inc +1.92% 068270.KS Celltrion Inc +2.00% ABVX Abivax SA -1.20%

Company Profile

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.